

Complete Summary

GUIDELINE TITLE

Role of imaging in second and third trimester bleeding.

BIBLIOGRAPHIC SOURCE(S)

Thurmond A, Fleischer AC, Andreotti RF, Bohm-Velez M, Fishman EK, Horrow MM, Hricak H, Zelop C, Expert Panel on Women's Imaging. Role of imaging in second and third trimester bleeding. [online publication]. Reston (VA): American College of Radiology (ACR); 2005. 2 p. [8 references]

GUIDELINE STATUS

This is the current release of the guideline.

It updates a previously published version: Thurmond A, Mendelson E, Bohm-Velez M, Bree R, Finberg H, Fishman EK, Hricak H, Laing F, Sartoris D, Goldstein S. Role of imaging in second and third trimester bleeding. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000 Jun;215 Suppl:895-7.

The appropriateness criteria are reviewed annually and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.

COMPLETE SUMMARY CONTENT

SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
QUALIFYING STATEMENTS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Second and third trimester vaginal bleeding

GUIDELINE CATEGORY

Diagnosis
Evaluation

CLINICAL SPECIALTY

Obstetrics and Gynecology
Radiology

INTENDED USERS

Health Plans
Hospitals
Managed Care Organizations
Physicians
Utilization Management

GUIDELINE OBJECTIVE(S)

To evaluate the appropriateness of radiologic examinations for patients with second and third trimester vaginal bleeding

TARGET POPULATION

Women in the second and third trimester of pregnancy who are experiencing vaginal bleeding

INTERVENTIONS AND PRACTICES CONSIDERED

1. Ultrasound (US), uterus
 - Transabdominal (TA) and repeat TA
 - Transperineal
 - Transvaginal
2. Magnetic resonance imaging (MRI), pelvis

MAJOR OUTCOMES CONSIDERED

Utility of radiologic examinations in differential diagnosis

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The guideline developer performed literature searches of peer-reviewed medical journals, and the major applicable articles were identified and collected.

NUMBER OF SOURCE DOCUMENTS

The total number of source documents identified as the result of the literature search is not known.

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Not Given)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not stated

METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review with Evidence Tables

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

One or two topic leaders within a panel assume the responsibility of developing an evidence table for each clinical condition, based on analysis of the current literature. These tables serve as a basis for developing a narrative specific to each clinical condition.

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus (Delphi)

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Since data available from existing scientific studies are usually insufficient for meta-analysis, broad-based consensus techniques are needed for reaching agreement in the formulation of the appropriateness criteria. The American College of Radiology (ACR) Appropriateness Criteria panels use a modified Delphi technique to arrive at consensus. Serial surveys are conducted by distributing questionnaires to consolidate expert opinions within each panel. These questionnaires are distributed to the participants along with the evidence table and narrative as developed by the topic leader(s). Questionnaires are completed by the participants in their own professional setting without influence of the other members. Voting is conducted using a scoring system from 1 to 9, indicating the least to the most appropriate imaging examination or therapeutic procedure. The survey results are collected, tabulated in anonymous fashion, and redistributed after each round. A maximum of three rounds is conducted and opinions are unified to the highest degree possible. Eighty percent agreement is considered a consensus. This modified Delphi technique enables individual, unbiased expression, is economical, easy to understand, and relatively simple to conduct.

If consensus cannot be reached by this Delphi technique, the panel is convened and group consensus techniques are utilized. The strengths and weaknesses of each test or procedure are discussed and consensus reached whenever possible.

If "No consensus" appears in the rating column, reasons for this decision are added to the comment sections.

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Internal Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Criteria developed by the Expert Panels are reviewed by the American College of Radiology (ACR) Committee on Appropriateness Criteria.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

ACR Appropriateness Criteria®

Clinical Condition: Second and Third Trimester Vaginal Bleeding

Variant 1: No other signs or symptoms.

Radiologic Exam Procedure	Appropriateness Rating	Comments
US, pregnant, uterus, transabdominal (TA)	9	
US, pregnant, uterus, transperineal	8	
US, pregnant, uterus, transperineal	6	
MRI, pelvis	2	
Appropriateness Criteria Scale 1 2 3 4 5 6 7 8 9 1 = Least appropriate 9 = Most appropriate		

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 2: Internal cervical os not visible by transabdominal ultrasound.

Radiologic Exam Procedure	Appropriateness Rating	Comments
US, pregnant, uterus, transperineal	9	
US, pregnant, uterus, transvaginal	8	
US, pregnant, uterus, repeat TA	4	
MRI, pelvis	2	
Appropriateness Criteria Scale 1 2 3 4 5 6 7 8 9 1 = Least appropriate 9 = Most appropriate		

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Variant 3: Placenta previa diagnosed before 32 weeks.

Radiologic Exam Procedure	Appropriateness Rating	Comments
US, pregnant, uterus, 32-34 weeks	8	
US, pregnant, uterus, once per month	4	
Appropriateness Criteria Scale 1 2 3 4 5 6 7 8 9 1 = Least appropriate 9 = Most appropriate		

Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.

Vaginal bleeding after the first trimester of pregnancy and before term may be due to premature delivery, placenta previa, placental abruption, placenta accreta or its variants, or of unknown origin. Placenta previa can be excluded if the placenta is shown to lie away from the internal os of the cervix, which can almost always be accomplished by transabdominal ultrasound examination of the cervix and lower uterine segment with the bladder full. If the anatomy is obscured by the fetal head, by hematoma, by a suspected lower uterine segment contraction,

or by an overly full bladder, transperineal scanning or more commonly transvaginal scanning with the bladder empty will almost always result in the correct diagnosis. MRI has been suggested as an alternative to transvaginal or transperineal scanning if ultrasound is inconclusive; however, MRI is rarely needed.

Placenta previa diagnosed in the second trimester may not persist until term because of growth of the lower uterine segment. One should avoid the use of terms such as "low-lying placenta," "marginal previa," "total previa," or "complete previa" since these terms are vague and difficult to quantify. It is better to describe the relationship of the inferior placenta to the internal cervical os in centimeters. If a placenta extends to, or partially covers, the internal os of the cervix before 28 weeks gestation, there is a 4% to 5% chance it will persist in this abnormal location until term, as compared to more than a 50% chance if it completely covers the os at 28 weeks. At any point in gestation if the placenta covers the cervix and is fully implanted on both the anterior and posterior walls of the lower uterine segment, placenta location is unlikely to change.

Placental abruption can be imaged by ultrasound. However, the echogenicity of clot and the echogenicity of placenta can be similar, and therefore a normal exam does not exclude abruption. In general, in a patient with second or third trimester bleeding, in the absence of diagnosis of placenta previa by ultrasound, the management of the pregnancy depends on the clinical circumstances. If clinical circumstances or ultrasound findings are confusing, MRI may help better define the location of the placenta and the presence of abruption

Abbreviations

- MRI, magnetic resonance imaging
- TA, transabdominal
- US, ultrasound

CLINICAL ALGORITHM(S)

Algorithms were not developed from criteria guidelines.

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The recommendations are based on analysis of the current literature and expert panel consensus.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

Selection of appropriate radiologic imaging procedures for the evaluation of patients with second and third trimester vaginal bleeding

POTENTIAL HARMS

Not stated

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

An American College of Radiology (ACR) Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists, and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those exams generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the U.S. Food and Drug Administration (FDA) have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

IMPLEMENTATION TOOLS

Personal Digital Assistant (PDA) Downloads

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better

IOM DOMAIN

Effectiveness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Thurmond A, Fleischer AC, Andreotti RF, Bohm-Velez M, Fishman EK, Horrow MM, Hricak H, Zelop C, Expert Panel on Women's Imaging. Role of imaging in second and third trimester bleeding. [online publication]. Reston (VA): American College of Radiology (ACR); 2005. 2 p. [8 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1996 (revised 2005)

GUIDELINE DEVELOPER(S)

American College of Radiology - Medical Specialty Society

SOURCE(S) OF FUNDING

The American College of Radiology (ACR) provided the funding and the resources for these ACR Appropriateness Criteria®.

GUIDELINE COMMITTEE

Committee on Appropriateness Criteria, Expert Panel on Women's Imaging

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Panel Members: Amy Thurmond, MD; Arthur C. Fleischer, MD; Rochelle F. Andreotti, MD; Marcela Böhm-Vélez, MD; Elliot K. Fishman, MD; Mindy M. Horrow, MD; Hedvig Hricak, MD, PhD; Carolyn Zelop, MD

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

It updates a previously published version: Thurmond A, Mendelson E, Bohm-Velez M, Bree R, Finberg H, Fishman EK, Hricak H, Laing F, Sartoris D, Goldstein S. Role of imaging in second and third trimester bleeding. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000 Jun;215 Suppl:895-7.

The appropriateness criteria are reviewed annually and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the [American College of Radiology \(ACR\) Web site](#).

ACR Appropriateness Criteria® Anytime, Anywhere™ (PDA application). Available from the [ACR Web site](#).

Print copies: Available from the American College of Radiology, 1891 Preston White Drive, Reston, VA 20191. Telephone: (703) 648-8900.

AVAILABILITY OF COMPANION DOCUMENTS

The following is available:

- ACR Appropriateness Criteria®. Background and development. Reston (VA): American College of Radiology; 2 p. Electronic copies: Available in Portable Document Format (PDF) from the [American College of Radiology \(ACR\) Web site](#).

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI February 13, 2006.

COPYRIGHT STATEMENT

Instructions for downloading, use, and reproduction of the American College of Radiology (ACR) Appropriateness Criteria® may be found on the [ACR Web site](#).

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2006 National Guideline Clearinghouse

Date Modified: 10/9/2006

